Skip to Main ContentSkip to FooterSkip to Search
  1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Drug Substance Manufacturing
  6.  » Designing Optimized, Site-Specific ADCs

Designing Optimized, Site-Specific ADCs

Summary: Antibody-drug conjugates have provided a breakthrough in targeted medicines but ways of increasing their stability and efficacy are still required. Historically, the technologies used to build these two approved products result in a heterogeneous milieu of conjugates. These mixtures of ADCs have been plagued with manufacturing challenges due to batch-to-batch variability and complicated analytics.Catalent highlights how these goals can be achieved using its technology platforms to produce site-specific ADCs.

Click here to download article.

For more information, please download two more articles in the series:

Whitepaper: Drug Development and Discovery April 2014

Whitepaper: Bioprocess International October 2014